to lysosomes, where they are degraded and recycled to sustain metabolism and to enable survival during starvation 1-5 . Acute, whole-body deletion of the essential autophagy gene Atg7 in adult mice causes a systemic metabolic defect that manifests as starvation intolerance and gradual loss of white adipose tissue, liver glycogen and muscle mass 1 . Cancer cells also benefit from autophagy. Deletion of essential autophagy genes impairs the metabolism, proliferation, survival and malignancy of spontaneous tumours in models of autochthonous cancer 6,7 . Acute, systemic deletion of Atg7 or acute, systemic expression of a dominant-negative ATG4b in mice induces greater regression of KRAS-driven cancers than does tumour-specific autophagy deletion, which suggests that host autophagy promotes tumour growth 1,8 . Here we show that hostspecific deletion of Atg7 impairs the growth of multiple allografted tumours, although not all tumour lines were sensitive to host autophagy status. Loss of autophagy in the host was associated with a reduction in circulating arginine, and the sensitive tumour cell lines were arginine auxotrophs owing to the lack of expression of the enzyme argininosuccinate synthase 1. Serum proteomic analysis identified the arginine-degrading enzyme arginase I (ARG1) in the circulation of Atg7-deficient hosts, and in vivo arginine metabolic tracing demonstrated that serum arginine was degraded to ornithine. ARG1 is predominantly expressed in the liver and can be released from hepatocytes into the circulation. Liver-specific deletion of Atg7 produced circulating ARG1, and reduced both serum arginine and tumour growth. Deletion of Atg5 in the host similarly regulated circulating arginine and suppressed tumorigenesis, which demonstrates that this phenotype is specific to autophagy function rather than to deletion of Atg7. Dietary supplementation of Atg7-deficient hosts with arginine partially restored levels of circulating arginine and tumour growth. Thus, defective autophagy in the host leads to the release of ARG1 from the liver and the degradation of circulating arginine, which is essential for tumour growth; this identifies a metabolic vulnerability of cancer.
Autophagy captures intracellular components and delivers them
to lysosomes, where they are degraded and recycled to sustain metabolism and to enable survival during starvation [1] [2] [3] [4] [5] . Acute, whole-body deletion of the essential autophagy gene Atg7 in adult mice causes a systemic metabolic defect that manifests as starvation intolerance and gradual loss of white adipose tissue, liver glycogen and muscle mass 1 . Cancer cells also benefit from autophagy. Deletion of essential autophagy genes impairs the metabolism, proliferation, survival and malignancy of spontaneous tumours in models of autochthonous cancer 6, 7 . Acute, systemic deletion of Atg7 or acute, systemic expression of a dominant-negative ATG4b in mice induces greater regression of KRAS-driven cancers than does tumour-specific autophagy deletion, which suggests that host autophagy promotes tumour growth 1, 8 . Here we show that hostspecific deletion of Atg7 impairs the growth of multiple allografted tumours, although not all tumour lines were sensitive to host autophagy status. Loss of autophagy in the host was associated with a reduction in circulating arginine, and the sensitive tumour cell lines were arginine auxotrophs owing to the lack of expression of the enzyme argininosuccinate synthase 1. Serum proteomic analysis identified the arginine-degrading enzyme arginase I (ARG1) in the circulation of Atg7-deficient hosts, and in vivo arginine metabolic tracing demonstrated that serum arginine was degraded to ornithine. ARG1 is predominantly expressed in the liver and can be released from hepatocytes into the circulation. Liver-specific deletion of Atg7 produced circulating ARG1, and reduced both serum arginine and tumour growth. Deletion of Atg5 in the host similarly regulated circulating arginine and suppressed tumorigenesis, which demonstrates that this phenotype is specific to autophagy function rather than to deletion of Atg7. Dietary supplementation of Atg7-deficient hosts with arginine partially restored levels of circulating arginine and tumour growth. Thus, defective autophagy in the host leads to the release of ARG1 from the liver and the degradation of circulating arginine, which is essential for tumour growth; this identifies a metabolic vulnerability of cancer.
To validate whether host autophagy promotes tumour growth, we tested the growth of an autophagy-competent C57Bl/6J isogenic Braf V600E/+ Pten −/− Cdkn2a −/− mouse melanoma cell line (termed YUMM 1.1) in C57Bl/6J host mice, without (Atg7 +/+ ) and with (Atg7 Δ/Δ ) conditional whole-body Atg7 deficiency (Fig. 1a ). YUMM 1.1 tumours were significantly smaller when grown in Atg7 Δ/Δ hosts compared to Atg7 +/+ hosts (Fig. 1b) , demonstrating that host autophagy promoted tumour growth. The examination of additional cell linesautophagy-competent isogenic C57Bl/6J Braf V600E/+ Pten −/− Cdkn2a −/− YUMM 1.3 melanoma, carcinogen-induced MB49 urothelial carcinoma and Kras G12D/+ p53 −/− (p53 is also known as Trp53) 71.8 non-small-cell lung cancer cells-revealed a similar requirement for host autophagy for tumour growth (Extended Data Fig. 1a, c, e ). The decreased tumour growth observed in Atg7 Δ/Δ hosts was associated with decreased proliferation. In some tumour types, there was also increased apoptosis ( Fig. 1c , Extended Data Fig. 1b , d, f). However, host autophagy was not required for the growth of autophagy-competent isogenic C57Bl/6J Braf V600E/+ Pten −/− Cdkn2a −/− YUMM 1.7 and 1.9 melanoma cell lines (Extended Data Fig. 2a-d ), which indicates that-although dependency on host autophagy is common-there are tumour-specific adaptation mechanisms.
The melanoma cell lines that are dependent on host autophagy for tumour growth are derived from genetically engineered mouse models of cancer, and therefore have a low mutation burden, low neoantigen load and fail to provoke an efficient T cell response 9 . Nonetheless, autophagy modulates a variety of immune mechanisms that could underlie defective tumour growth in autophagy-deficient hosts. Atg7 Δ/Δ hosts did not modify infiltration of YUMM 1.1 tumours with CD3 + , CD4 + or CD8 + cells (Extended Data Fig. 2e ). Depletion of CD4 + and CD8 + T cells modestly increased tumour growth in Atg7 +/+ hosts but did not significantly rescue growth in Atg7 Δ/Δ hosts (Extended Data Fig. 2f ). Thus, despite the relative increase in the fraction of myeloid-derived suppressor cells and CD8 + T cells in Atg7 Δ/Δ hosts (Extended Data Fig. 2g ), the decreased tumour growth in Atg7 Δ/Δ hosts was not due to the induction of an anti-tumour T cell response.
Autophagy supports metabolism by recycling cargo to provide anabolic and catabolic substrates 6 . This metabolic recycling function of autophagy promotes mammalian survival during fasting 1-3 , and tumour cell survival under conditions of nutrient limitation 4,10,11 . One major source of tumour nutrients is the host blood supply. Accordingly, we tested whether circulating nutrients provided by host autophagy were required for tumour growth. Metabolite profiling of serum from Atg7 +/+ and Atg7 Δ/Δ hosts identified 12 metabolites that were decreased and 7 that were increased with autophagy knockout ( Fig. 1d , Supplementary Tables 1, 2 ). Serum arginine was notably downregulated in Atg7 Δ/Δ compared to Atg7 +/+ hosts (−2.37 fold change (log 2 (serum arginine in Atg7 Δ/Δ /serum arginine in Atg7 +/+ )) ( Fig. 1d ), confirming previous results 1 .
Arginine is a non-essential amino acid derived from the diet, de novo synthesis and protein turnover, and is important for mTOR activation 12 , ammonia detoxification through the urea cycle as well as the synthesis of proteins, creatine, polyamines and nitric oxide 13 . It has long been known that some human cancers silence expression of ASS1, the gene that encodes argininosuccinate synthase 1 (ASS1), which results in arginine auxotrophy 14 . Without ASS1, cancer cells are unable to synthesize arginine from citrulline and are dependent Letter reSeArCH on exogenous arginine 15, 16 . ASS1 silencing prevents consumption of aspartate by the urea cycle, increasing the availability of this amino acid-which is required for pyrimidine biosynthesis and can become limiting in hypoxia 17, 18 (Fig. 1e ). These findings suggested that low circulating arginine may underlie defective tumour growth in autophagy-deficient hosts. 
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To determine their requirement for exogenous arginine, YUMM 1.1, 1.3, 1.7, 1.9, MB49 and 71.8 cells were tested for growth without and with arginine. Proliferation was blocked in vitro in complete medium with the sole absence of arginine, and this was not associated with cell death. Growth rates increased with an increased percentage of arginine in the medium, which demonstrates arginine auxotrophy ( Fig. 1f , Extended Data Fig. 3a ). YUMM 1.1 tumours were tested for the lack of expression of enzymes involved in arginine biosynthesis: ASS1, argininosuccinate lyase (ASL)-which converts citrulline to arginine-and ornithine transcarbamylase (OTC), which converts ornithine to citrulline ( Fig. 1e ). As previously shown for melanoma 19, 20 , and irrespective of the use of Atg7 +/+ and Atg7 Δ/Δ hosts, tumours lacked ASS1 and OTC expression, which explains their arginine auxotrophy ( Fig. 1g ). In contrast to tumours, both Atg7 +/+ and Atg7 Δ/Δ hosts express ASS1, ASL and OTC in liver and ASS1 and ASL in kidney, which suggests that they are capable of arginine synthesis (Extended Data Fig. 3b ). Consistent with findings from the YUMM 1.1 line and the literature [14] [15] [16] , YUMM 1.7 tumours that grew on Atg7 Δ/Δ hosts also lacked expression of ASS1 and OTC, which suggests that-in a subset of tumour cell lines-there is a mechanism of intrinsic resistance that is independent of arginine auxotrophy (Extended Data Fig. 3c ).
To determine how circulating arginine is depleted in Atg7 Δ/Δ hosts, we examined the serum proteome by nanoscale liquid chromatography coupled to tandem mass spectrometry (nano LC-MS/MS), which identified 19 proteins that were downregulated and 32 that were upregulated upon loss of Atg7 ( Fig. 2a , Supplementary Table 3 ). ARG1 was among the proteins that were upregulated in the serum of Atg7 Δ/Δ hosts (2.43 fold change (log 2 (ARG1 in Atg7 Δ/Δ /ARG1 in Atg7 +/+ )) ( Fig. 2b ). ARG1 is expressed in the liver, where it degrades arginine to ornithine. The appearance of ARG1 in serum, without altered levels in the liver, in Atg7 Δ/Δ hosts was confirmed by western blotting (Fig. 2c ). Levels of nitric oxide in serum were not modified, which suggests that serum ARG1 did not alter the arginine availability for nitric oxide synthesis (Extended Data Fig. 3d ). Serum ARG1 activity in vitro was increased, as shown by greater rates of degradation of 13 C 6 -arginine to 13 C 5 -ornithine in serum from Atg7 Δ/Δ hosts (Extended Data Fig. 4a ). To determine how Atg7 deficiency altered arginine metabolism in vivo, we infused Atg7 +/+ and Atg7 Δ/Δ hosts with 13 C 6 15 N 4 -labelled arginine, for three hours 21 (Fig. 2d ). To analyse 13 C and 15 N enrichment, serum was collected at different times during infusion, and tumours, kidneys and livers were collected at the end of the three-hour infusion. The serum of Atg7 Δ/Δ hosts showed decreased arginine ( 12 C, 13 Letter reSeArCH observed in levels of arginine, citrulline or ornithine in the livers of Atg7 Δ/Δ hosts compared to Atg7 +/+ hosts (Extended Data Fig. 4c, d) . Tumours from Atg7 Δ/Δ hosts also displayed decreased levels of arginine ( 12 C, 13 (Fig. 2f) . These results confirm that arginine is depleted in ASS1-deficient tumours that are dependent on exogenous arginine, which is consistent with insufficient circulating arginine in Atg7 Δ/Δ hosts.
During inflammation, injury and liver disease, ARG1 is released from hepatocytes into circulation, which leads to arginine depletion 22 . Atg7 Δ/Δ hosts have steatosis 1 , and liver-specific deletion of Atg5 or Atg7 is associated with liver damage 2, 23, 24 . Accordingly, we hypothesized that ARG1 is released into circulation after deletion of Atg7 in the liver. To test this hypothesis, we deleted Atg7 specifically in the liver and examined levels of arginine and ARG1 in circulation, and tumour growth (Fig. 3a) . Injection of an AAV-TBG-iCre vector efficiently deleted Atg7 in the liver, but not in other organs such as the brain and kidney (Extended Data Fig. 5a-c) . As expected, liver-specific deletion of Atg7 led to histopathologic changes in liver cells without affecting other tissues (Extended Data Fig. 5d ). As seen in Atg7 Δ/Δ hosts, serum from hosts with liver-specific deletion of Atg7 showed increased levels of ARG1 (Fig. 3b ), a reduced level of arginine, an increased level of ornithine ( Fig. 3c ) and no change in the level of nitric oxide (Extended Data Fig. 5e ). Liver-specific deletion of Atg7 also modified levels of other circulating metabolites, with 18 increased and 4 decreased compared to Atg7 +/+ hosts ( Supplementary Tables 4, 5 ). Some of these circulating metabolites (for example, 4-pyridoxic acid, d-gluconate and glucuronic acid) were also altered in Atg7 Δ/Δ hosts, which suggests that the dysregulation of these metabolites has a liver-specific origin (Fig. 1d, Extended Data Fig. 5f ). The level of arginine in serum was downregulated in hosts with liver-specific deletion of Atg7 compared to Atg7 +/+ hosts (Fig. 3d ), as was shown in Atg7 Δ/Δ hosts (Fig. 1d) . The weight and volume of YUMM 1.1 melanoma tumours were significantly decreased in hosts with liver-specific deletion of Atg7, compared to Atg7 +/+ hosts (Fig. 3e) ; this decrease in weight and volume was associated with decreased proliferation and no change in apoptosis ( Fig. 3f ). Tumours from hosts with liver-specific deletion of Atg7 had decreased levels of arginine and increased levels of ornithine, but to a lesser extent than the tumours from Atg7 Δ/Δ hosts-this may explain why the decreased tumour growth in hosts with liver-specific deletion of Atg7 was not as marked as with Atg7 Δ/Δ hosts (Fig. 3g ). In hosts with liver-specific deletion of Atg7, autophagy in the microenvironment may locally feed the tumour with amino acids, as has previously been shown in pancreatic cancer and Drosophila tumours 25, 26 . These results suggest that deletion of Atg7 in the liver is responsible for ARG1 release into the circulation, which leads to depletion of circulating arginine and decreased tumour growth.
To determine whether the degradation of circulating arginine by ARG1 in Atg7 Δ/Δ hosts was due to loss of autophagy, we examined mice with conditional deletion of Atg5. Whole-body conditional deletion of Atg5 also introduced ARG1 into circulation and decreased the level of arginine in serum; tumour growth was also decreased in these Atg5 Δ/Δ hosts (Extended Data Fig. 6 ). Similar to liver-specific deletion of Atg7, liver-specific deletion of Atg5 led to histopathologic changes in the liver with increased circulating ARG1 and reduced arginine (Extended Data Fig. 7) , which confirms that the modulation of circulating arginine and tumorigenesis was dependent on autophagy.
We next tested whether dietary arginine supplementation can rescue tumour growth in Atg7 Δ/Δ hosts (Fig. 4a ). Dietary arginine supplementation was able to partially increase levels of arginine in serum in Atg7 Δ/Δ hosts, and did not modify levels of ornithine or citrulline (Fig. 4b ). This increased circulating arginine promoted growth and proliferation of the YUMM 1.1 and 1.3 melanoma cell lines in Atg7 Δ/Δ hosts, compared to Atg7 +/+ hosts (Fig. 4c, d, Extended Data Fig. 8a-c) , confirming that limiting circulating arginine can curtail tumour growth.
In summary, autophagy in the liver prevents the release of ARG1 and the degradation of circulating arginine that is important for the growth of arginine-auxotrophic tumours (Fig. 4e ). However, some tumour cells that are auxotrophic for arginine in vitro were capable of growth in Atg7 Δ/Δ hosts, suggesting that adaptation mechanisms exist 27 . Recent Letter reSeArCH work has demonstrated that autophagy in the local tumour microenvironment can provide amino acids that promote tumour growth 25, 26 . Our work demonstrates that host autophagy also sustains a circulating amino acid-arginine-that is essential for tumour growth. This finding underscores the importance of understanding the sensitivity of ASS1-deficient tumours to arginine deprivation therapy 28 , with or without autophagy inhibition 29 . As tumour nutrients are mainly derived from host circulation, restricting essential tumour nutrients in the circulation-as done with asparaginase treatment-is a form of cancer therapy that is ripe for further exploitation 30 .
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MEthodS
Mice. All animal care and treatments were carried out in compliance with Rutgers University Institutional Animal Care and Use Committee guidelines (IACUC). Mice for conditional whole-body deletion of Atg7 (C57Bl/6J Ubc-cre ERT2/+ ;Atg7 flox/flox ) were engineered with floxed alleles of Atg7 (Atg7 flox/flox ) 2 and a transgene expressing the TAM-regulated Cre recombinase fusion protein under the control of the ubiquitously expressed ubiquitin C promoter (Ubc) 31 , as previously described 1 . Acute deletion of Atg7 throughout the mouse is obtained after TAM injection 1 . TAM (T5648, Sigma) was suspended at a concentration of 20 mg/ml, in a mixture of 98% sunflower seed oil and 2% ethanol and 250 μl per 25 g of body weight was injected intraperitoneally into 8-10-week-old male Ubc-cre ERT2/+ ;Atg7 +/+ or Ubc-cre ERT2/+ ;Atg7 flox/flox mice once per day for four days to generate cohorts of Atg7-deleted (Atg7 Δ/Δ ) and wild-type (Atg7 +/+ ) control host mice. To assess the consequence of acute deletion of Atg7 on tumorigenesis of C57Bl/6J isogenic male tumour cells, one week after TAM treatment, YUMM 1.1 (1 × 10 6 cells), 1.3 (2 × 10 6 cells), 1.7 (0.1 × 10 6 cells), 1.9 (1 × 10 6 cells), 71.8 (1 × 10 6 cells) or MB49 (0.25 × 10 6 cells) cells were resuspended in 100 μl PBS and injected subcutaneously into the dorsal flanks of mice. Three weeks after cell injection, mice were killed and serum and tumours were collected. The maximal tumour volume (1,700 mm 3 ) permitted by Rutgers University IACUC was never exceeded. For arginine supplementation, 1% arginine (A8094, Sigma) in drinking water was given to the mice a week before TAM and throughout the experiment.
Mice for conditional whole-body deletion of Atg5 (C57Bl/6J Ubc-cre ERT2/+ ;Atg5 flox/flox ) were engineered with floxed alleles of Atg5 (Atg5 flox/flox ) 32 and a transgene expressing the TAM-regulated Cre recombinase fusion protein under the control of the Ubc promoter 31 . Acute deletion of Atg5 throughout mice was obtained after TAM injection (250 μl of TAM per 25 g of body weight injected intraperitoneally into 8-10-week-old male Ubc-cre ERT2/+ ;Atg5 +/+ or Ubc-cre ERT2/+ ;Atg5 flox/flox mice once a week for four weeks) to generate cohorts of Atg5-deleted (Atg5 Δ/Δ ) and wild-type (Atg5 +/+ ) control host mice.
Liver-specific deletion of Atg7 and Atg5 was achieved by injecting an adeno-associated virus (AAV)-thyroxine binding globulin (TBG) promoter-Cre recombinase vector (AAV-TBG-iCre, Vector Biolabs) into Atg7 flox/flox and Atg5 flox/flox mice. An AAV-TBG promoter-GFP vector (AAV-TBG-GFP, Vector Biolabs) was injected into Atg7 flox/flox and Atg5 flox/flox mice as a control. 1.5 × 10 11 genome copies of either AAV-TBG-iCre or AAV-TBG-GFP vectors in 100 μl PBS were injected into the tail vein of 8-10-week-old male Atg7 flox/flox and Atg5 flox/flox mice to generate liver-specific Atg7 Δ/Δ or Atg5 Δ/Δ and Atg7 +/+ or Atg5 +/+ control mice, respectively. Three weeks post injection, YUMM 1.1 cells (1 × 10 6 cells) were resuspended in 100 μl PBS and injected subcutaneously into the dorsal flanks of the liver-specific Atg7 Δ/Δ and Atg7 +/+ control mice. Tumour growth was monitored daily. Tumour volume was calculated with the following formula: volume = π/6 × L × W × H. Three weeks after cell injection, mice were killed and liver, kidney, brain, serum and tumours were collected. Cell lines. Cell culture. Cell lines were authenticated using whole-exome sequencing. YUMM 1.1, 1.3, 1.7 and 1.9 cells derived from Braf V600E/+ Pten −/− Cdkn2a −/− C57Bl/6J mouse melanomas were previously generated 33 and cultured in Dulbecco's minimum essential medium and Ham's F12 (DMEM-F12) (10-092-CV, Corning) supplemented with 10% fetal bovine serum (FBS) (F0926, Sigma) in a 5% CO 2 incubator at 37 °C. The mouse lung cancer cell line 71.8 was previously derived from p53 −/− Kras G12D/+ mouse lung tumours 11 and the MB49 cell line 34 was provided by the Ratliff laboratory and cultured in Roswell Park Memorial Institute medium (RPMI) (11875-093, Gibco). Cells were tested negative for mycoplasma contamination. Cell proliferation in arginine-deficient medium. YUMM 1.1, 1.3, 1.7, 1.9, 71.8 and MB49 cells were seeded at a density of 15,000 cells per well in 24-well plates. The following day, cells were washed with phosphate-buffered saline (PBS) (14190-144, Gibco) and cultured in arginine-free DMEM-F12 (DFL27, Caisson Labs) or arginine-free RPMI (R1780, Sigma) supplemented with 10% dialysed FBS (89986, Thermo Scientific) and an increasing percentage of arginine from 2.5 to 100%. Growth was assessed using an IncuCyte ZOOM with images of the proliferative cells recorded every 2 h for a total duration of 6 days. Metabolite analysis by LC-MS. Metabolite extraction for LC-MS. Metabolites from 10-μl serum samples were first extracted with 40 μl of ice-cold methanol. The mixture was allowed to sit at −20 °C for 20 min, and then centrifuged at 16,000g for 10 min at 4 °C. Supernatants were transferred to clean tubes and pellets were extracted again with 200 μl 40:40:20 methanol:acetonitrile:H 2 O. The mixture was allowed to sit on ice for 10 min, and then centrifuged at 16,000g for 10 min at 4 °C. Supernatants were combined with the first extraction, resulting in roughly 240 μl of extract. Extracts were further processed with Phree Phospholipid Removal 1-ml Tube (Phenomenex), according to the manufacturer's instructions. The final extract was stored at −80 °C until analysis by LC-MS. To extract metabolites from the tissues and tumours, samples (25 mg) were first pulverized using a Cryomill (Retsch) in liquid nitrogen at 25 Hz for 2 min. Extraction was performed by adding −20 °C 40:40:20 methanol:acetonitrile:water with 0.5% formic acid solution (500 μl) to the ground samples, followed by vortexing and centrifugation at 16,000g for 10 min at 4 °C. The supernatants were transferred to clean tubes and the pellets were extracted again by repeating the previous step. The supernatant was then combined with the first extract. Then, 500 μl of extract was neutralized with 44 μl of 15% NH 4 HCO 3 solution and centrifuged at 16,000g for 10 min at 4 °C to remove protein precipitate. Then, 300 μl of supernatant was removed to clean tubes and stored at −80 °C until analysis by LC-MS. LC-MS analysis. LC-MS analysis of the extracted metabolites was performed on a Q Exactive PLUS hybrid quadrupole-orbitrap mass spectrometer (Thermo Fisher Scientific) coupled to hydrophilic interaction chromatography. The LC separation was performed on an UltiMate 3000 UHPLC system with an XBridge BEH Amide column (150 mm × 2.1 mm, 2.5 μM particle size, Waters) with the corresponding XP VanGuard Cartridge. The liquid chromatography used a gradient of solvent A (95%:5% H 2 O:acetonitrile with 20 mM ammonium acetate, 20 mM ammonium hydroxide, pH 9.4), and solvent B (20%:80% H 2 O:acetonitrile with 20 mM ammonium acetate, 20 mM ammonium hydroxide, pH 9.4). The gradient was 0 min, 100% B; 3 min, 100% B; 3.2 min, 90% B; 6.2 min, 90% B; 6.5 min, 80% B; 10.5 min, 80% B; 10.7 min, 70% B; 13.5 min, 70% B; 13.7 min, 45% B; 16 min, 45% B; 16.5 min, 100% B. The flow rate was 300 μl/min. Injection volume was 5 μl and column temperature 25 °C. The mass spectrometry scans were in negative-ion mode with a resolution of 70,000 at m/z 200. The automatic gain control target was 3 × 10 6 and the scan range was 75−1,000. To increase metabolome coverage, the samples were also analysed with a secondary LC-MS method, which involves two separate instrument platforms covering both positively charged and negatively charged metabolites. Negatively charged metabolites were analysed via reverse-phase ion-pairing chromatography coupled to an Exactive orbitrap mass spectrometer (Thermo Fisher Scientific). The mass spectrometer was operated in negative ion mode with resolving power of 100,000 at m/z 200, scanning range being m/z 75-1,000. The liquid chromatography method has previously been described 35 , using a Synergy Hydro-RP column (100 mm × 2 mm, 2.5 μm particle size, Phenomenex) with a flow rate of 200 μl/min. The liquid chromatography gradient was 0 min, 0% B; 2.5 min, 0% B; 5 min, 20% B; 7.5 min, 20% B; 13 min, 55% B; 15.5 min, 95% B; 18.5 min, 95% B; 19 min, 0% B; 25 min, 0% B. Solvent A is 97:3 water:methanol with 10 mM tributylamine and 15 mM acetic acid; solvent B is methanol. Positively charged metabolites were analysed on a Q Exactive Plus mass spectrometer coupled to Vanquish UHPLC system (Thermo Fisher Scientific). The mass spectrometer was operated in positive-ion mode with resolving power of 140,000 at m/z 200, scanning range being m/z 75-1,000. The liquid chromatography separation was achieved on an Agilent Poroshell 120 Bonus-RP column (150 × 2.1 mm, 2.7 μm particle size). The gradient was 0 min, 50 μl/min, 0.0%B; 6 min, 50 μl/min, 0% B; 12 36 . Metabolite features were extracted in MAVEN v.707 37 with the labelled isotope specified and a mass accuracy window of 5 p.p.m. For the 13 C 15 N arginine infusions, the isotope natural abundance and impurity of labelled substrate was corrected using a matrix-based algorithm. Labelled arginine infusion. For jugular vein catheterization, the procedure was modified from work previously described 38 . In brief, Atg7 Δ/Δ and Atg7 +/+ mice were anaesthetized using isoflurane carried by oxygen, followed by placement of a central venous catheter (polyurethane tubing, 1 F in OD) (SAI Infusion Technologies) into the right jugular vein. A minimal amount of blood was carefully withdrawn to verify the catheter patency. Afterwards, the saline solution in the catheter was replaced by heparin-glycerol catheter lock solution (SAI Infusion Technologies). The proximal end of the catheter was then tunnelled subcutaneously, exited between the shoulder blades and properly secured. A fully recovered surgical mouse was placed in a plastic harness (SAI Infusion Technologies), and the catheter was connected to an infusion pump (New Era Pump System) through a mouse tether and swivel system (Instech Laboratories). Arginine isotope tracer ( 13 C 6 15 N 4 , CNLM-539-H-PK, Cambridge Isotope Laboratories) was dissolved in sterile saline and infused at a rate of 3.5 nmol/g/min (0.1 μl/g/min) for 3 h. Infusion rate was determined using turnover flux calculations 21 . Mice were killed after infusion for serum, tumour, liver and kidney analysis by LC-MS. The isotope natural abundance and impurity of labelled substrate was corrected using a matrix-based algorithm. The construction of the purity matrix and C/N joint correction matrix is similar to AccuCor 39 . For calculation of the circulating amino acid concentration, the average ion counts from the Atg7 +/+ mice were normalized to the previously measured amino acid concentration 40 . The amino acid concentrations in the Atg7 Δ/Δ mice were calculated proportionally. Arginase activity assay. To follow conversion of arginine to ornithine, 15 μl serum samples were added to 5 μl of 9.7 mM MnCl 2 , 5 μl of 360 mM pH 9.7 glycine and 5 μl of 300 μM 13 C 6 -arginine followed by incubation at 37 °C for 0, 5, 20, 60 or 120 min. Then, 870 μl of 40:40:20 methanol:acetonitrile:water with 0.5% formic
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Extended Data Fig. 2 | Immune response is not involved in decreased tumour growth observed in Atg7 Δ/Δ hosts. a, c, Comparison of tumour weight between Atg7 +/+ (n = 5) and Atg7 Δ/Δ (a, n = 5; c, n = 6) hosts after injection of 1.7 (a) or 1.9 (c) cells. Data are mean ± s.e.m. b, d, Immunohistochemistry quantification of Ki-67 + and active caspase-3 + in 1.7 (b) and 1.9 (d) tumours from Atg7 +/+ and Atg7 Δ/Δ hosts. Data are mean ± s.e.m. e, Representative immunohistochemistry images and quantification of CD3 + , CD4 + and CD8 + cells in tumours from Atg7 +/+ and Atg7 Δ/Δ hosts. Data are mean ± s.e.m. f, Comparison of tumour volume and weight between Atg7 +/+ (n = 10), Atg7 +/+ + CD4 and CD8 antibody depletion (n = 15), Atg7 Δ/Δ (n = 7) and Atg7 Δ/Δ + CD4 and CD8 antibody depletion (n = 8) hosts. Data are mean ± s.e.m. *P < 0.05, ****P < 0.0001. g, Fold change in immune components between Atg7 +/+ and Atg7 Δ/Δ , with or without antibody depletion (n = 5 each). T reg , T regulatory cells; DC, dendritic cells; MDSC, myeloid-derived suppressor cells. Data are mean ± s.e.m. ***P < 0.001, ****P < 0.0001, by two-way ANOVA test. 
